Home > Press > BioSante Pharmaceuticals to Present at the Rodman & Renshaw
Abstract:
BioSante Pharmaceuticals, Inc. (Amex: BPA) today announced that Stephen M. Simes, the company's president and chief executive officer, will present a BioSante corporate and clinical overview at the Acumen BioFin Rodman and Renshaw Annual Healthcare Conference, taking place at the New York Palace Hotel in New York City, from November 5 to 7, 2007. Mr. Simes will present on November 5, 2007 at 4:05 p.m. local time.
BioSante Pharmaceuticals to Present at the Rodman & Renshaw
LINCOLNSHIRE, IL | Posted on October 31st, 2007
A live audio webcast of BioSante's presentation may be accessed at http://www.biosantepharma.com/investors/events.html and a replay will be available at the same link for 90 days.
Rodman & Renshaw, a full-service investment bank, is a leading investment banking firm to the biotechnology and pharmaceutical sectors. This conference will feature presentations from over 350 small and medium biotechnology and pharmaceutical companies, to an audience comprised of stock research analysts, institutional money managers, brokers and individual investors, as well as biotechnology and pharmaceutical industry representatives.
####
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Elestrin™ (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee, and LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD). Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, drug delivery, and aesthetic medicine.
For more information, please click here
Contacts:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
http://www.mckinneychicago.com
Copyright © Business Wire 2007
If you have a comment, please
Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
Nanomedicine
Nanotechnology could help fight diabetes: Injectable nanogel can monitor blood-sugar levels and secrete insulin when needed May 16th, 2013
Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013
Pitt Chemists Demonstrate Nanoscale Alloys So Bright They Could Have Potential Medical Applications: “Think about a particle that will not only help researchers detect cancer sooner but be used to treat the tumor, too.” May 15th, 2013
Using clay to grow bone: Researchers use synthetic silicate to stimulate stem cells into bone cells May 15th, 2013
Announcements
Artificial Forest for Solar Water-Splitting: Berkeley Lab Researchers Report First Fully Integrated Artificial Photosynthesis Nanosystem May 17th, 2013
Moth-Inspired Nanostructures Take the Color Out of Thin Films May 17th, 2013
NIA Public Briefing: Nanotechnology and the Council of Europe May 17th, 2013
Scientists capture first direct proof of Hofstadter butterfly effect May 17th, 2013
Events/Classes
Interactive Printed Products – New Applications Enabled by Organic and Printed Electronics May 16th, 2013
Nanometrics Announces Upcoming Investor Events May 14th, 2013
INSCX™ exchange to present a nanotechnology-based Emission Reduction Programme, Ankara, Turkey, June 2013 May 14th, 2013
VDMA: New “Photonics Industry Report 2013” presented May 14th, 2013